Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586892 · ClinicalTrials.gov registry record
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
A clinical trial of Orodental Injury, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06586892 is a study of Orodental Injury that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06586892, a study of Orodental Injury, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This research will focus on the prospective qualification and validation of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) candidate biomarkers (i.e., Ktrans and Ve) to assess the natural history of osteoradionecrosis (ORN) and treatment for this devastating complication related to irradiation of head and neck cancers. The investigations will also include assessment of DCE-MRI candidate biomarkers for pre-qualification as quantitative imaging biomarkers of soft-tissue structures.
Conditions Studied
Interventions
- BEHAVIORAL Radiotherapy followed by chemotherapy
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2032-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06586892
The ClinicalTrials.gov registry entry for NCT06586892 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Orodental Injury appearing as the primary indexed condition, and to 1 intervention - of which Radiotherapy followed by chemotherapy is the first listed.
NCT06586892 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06586892 about?
NCT06586892 is a clinical study titled "Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)". This research will focus on the prospective qualification and validation of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) candidate biomarkers (i.e., Ktrans and Ve) to assess the natural history of osteoradionecrosis (ORN) and treatment for this devastating complication related to i...
What is the current status of trial NCT06586892?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-09-15. Estimated completion is 2032-12-30.
What conditions does trial NCT06586892 study?
This clinical trial studies the following conditions: Orodental Injury.
What interventions are being tested in trial NCT06586892?
The interventions under investigation include: Radiotherapy followed by chemotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06586892?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586892 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.